<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937584</url>
  </required_header>
  <id_info>
    <org_study_id>PT003019</org_study_id>
    <nct_id>NCT02937584</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID)
      and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and
      resistance in subjects with moderate to severe chronic obstructive pulmonary disease (COPD)
      following chronic dosing after approximately two weeks treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2016</start_date>
  <completion_date type="Actual">May 28, 2018</completion_date>
  <primary_completion_date type="Actual">May 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific Image-Based Airway Volume (siVaw)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Specific image-based airway volume. Average across lobe, adjusted for lobe volume. Ratio to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific Image-based Airway Resistance (siRaw)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Specific image-based airway resistance (siRaw). Average across lobes, adjusted for lobe volume. Ratio to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image-based Airway Volume (iVaw)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Image-based airway volume (iVaw) without correction for lobe volume. Ratio to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image-based Airway Resistance (iRaw)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Image-based airway resistance (iRaw) without correction for lobe volume. Ratio to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>FEV1 Change from baseline in Forced Expiratory Volume at 1 second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Residual Capacity (FRC)</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Functional residual capacity (FRC). Ratio to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>COPD, Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>GP MDI (PT001) 14.4 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF MDI (PT005) 9.6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP MDI (PT001) 14.4 μg</intervention_name>
    <description>Glycopyrronium</description>
    <arm_group_label>GP MDI (PT001) 14.4 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF MDI (PT005) 9.6 μg</intervention_name>
    <description>Formoterol Fumarate</description>
    <arm_group_label>FF MDI (PT005) 9.6 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-child bearing potential (ie, physiologically incapable of becoming pregnant,
             including any female who is 2 years post-menopausal); or Child bearing potential, has
             a negative urine pregnancy test at Visit 1, and agrees to use acceptable contraceptive
             methods used consistently and correctly

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking.

               -  At Visit 1, FEV1/FVC ratio must be &lt;0.70

               -  At Visit 1, post-bronchodilator FEV1must be &gt;30% and &lt;80% predicted normal value,
                  calculated using The Third National Health and Nutrition Examination Survey
                  (NHANES III) reference equations.

        Exclusion criteria:

          -  Significant diseases other than COPD, i.e., disease or condition which, in the opinion
             of the Investigator, may put the subject at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study.

          -  Women who are pregnant or lactating, or are planning to become pregnant during the
             course of the study, or women of childbearing potential who are not using an
             acceptable method of contraception.

          -  Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.

          -  Subjects who have been hospitalized due to poorly controlled COPD within 3 months
             prior to Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).

          -  Subjects who have poorly controlled COPD, defined as acute worsening of COPD that
             requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to
             Visit 1 (Screening) or during the run-in period (Visit 1 to Visit 2).

          -  Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of
             whether or not they have been treated.

          -  Subjects who have a history of hypersensitivity to β2-agonists, glycopyrronium or
             other muscarinic anticholinergics, or any component of the MDI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Orevillo</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erpent</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4186&amp;filename=PT003019-01_FLUI-2015-140_Protocol_10%20August_Redacted_PDFA.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4186&amp;filename=PT003019-sap-16APR2018-Redacted_PDFA.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>May 10, 2019</results_first_submitted>
  <results_first_submitted_qc>June 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02937584/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02937584/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study randomized 23 subjects at 2 sites in Belgium from December 2016 to May 2018.</recruitment_details>
      <pre_assignment_details>Subjects were randomized into 1 of 2 treatment sequences. Sequence 1 received GP MDI in Period 1 followed by FF MDI in Period 2. Sequence 2 received FF MDI in Period 1 followed by GP MDI in Period 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GP MDI/ FF MDI</title>
          <description>Glycopyrronium Metered Dose Inhalation /Formoterol Fumarate Metered Dose Inhalation</description>
        </group>
        <group group_id="P2">
          <title>FF MDI/GP MDI</title>
          <description>Formoterol Fumarate Metered Dose Inhalation / Glycopyrronium Metered Dose Inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population - all subjects who were randomized to treatment. Treatment was assigned as randomized regardless of the treatment actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>ITT Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>ITT Population</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Specific Image-Based Airway Volume (siVaw)</title>
        <description>Specific image-based airway volume. Average across lobe, adjusted for lobe volume. Ratio to baseline</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI</title>
            <description>Glycopyrronium Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>FF MDI</title>
            <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Image-Based Airway Volume (siVaw)</title>
          <description>Specific image-based airway volume. Average across lobe, adjusted for lobe volume. Ratio to baseline</description>
          <population>ITT Population</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="1.02" upper_limit="1.22"/>
                    <measurement group_id="O2" value="1.23" lower_limit="1.14" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0187</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specific Image-based Airway Resistance (siRaw)</title>
        <description>Specific image-based airway resistance (siRaw). Average across lobes, adjusted for lobe volume. Ratio to baseline.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI</title>
            <description>Glycopyrronium Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>FF MDI</title>
            <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Image-based Airway Resistance (siRaw)</title>
          <description>Specific image-based airway resistance (siRaw). Average across lobes, adjusted for lobe volume. Ratio to baseline.</description>
          <population>ITT Population</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.59" upper_limit="0.95"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.44" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0219</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significance assessed using Hochberg's procedure applied across primary endpoints within each treatment</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image-based Airway Volume (iVaw)</title>
        <description>Image-based airway volume (iVaw) without correction for lobe volume. Ratio to baseline.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI</title>
            <description>Glycopyrronium Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>FF MDI</title>
            <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Image-based Airway Volume (iVaw)</title>
          <description>Image-based airway volume (iVaw) without correction for lobe volume. Ratio to baseline.</description>
          <population>ITT Population</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="1.01" upper_limit="1.24"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.12" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0283</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Image-based Airway Resistance (iRaw)</title>
        <description>Image-based airway resistance (iRaw) without correction for lobe volume. Ratio to baseline.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI</title>
            <description>Glycopyrronium Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>FF MDI</title>
            <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Image-based Airway Resistance (iRaw)</title>
          <description>Image-based airway resistance (iRaw) without correction for lobe volume. Ratio to baseline.</description>
          <population>ITT Population</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.59" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.41" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0304</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1</title>
        <description>FEV1 Change from baseline in Forced Expiratory Volume at 1 second.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI</title>
            <description>Glycopyrronium Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>FF MDI</title>
            <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1</title>
          <description>FEV1 Change from baseline in Forced Expiratory Volume at 1 second.</description>
          <population>ITT Population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.065" spread="0.193"/>
                    <measurement group_id="O2" value="0.151" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1582</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Mean Change from Baseline</param_type>
            <param_value>0.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0375</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Mean Change from Baseline</param_type>
            <param_value>0.151</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Residual Capacity (FRC)</title>
        <description>Functional residual capacity (FRC). Ratio to baseline.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI</title>
            <description>Glycopyrronium Metered Dose Inhalation</description>
          </group>
          <group group_id="O2">
            <title>FF MDI</title>
            <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Residual Capacity (FRC)</title>
          <description>Functional residual capacity (FRC). Ratio to baseline.</description>
          <population>ITT Population</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" lower_limit="0.891" upper_limit="1.073"/>
                    <measurement group_id="O2" value="0.938" lower_limit="0.833" upper_limit="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6176</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.978</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.891</ci_lower_limit>
            <ci_upper_limit>1.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2699</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within-group comparison to baseline using paired test</method_desc>
            <param_type>Geometric mean ratio to baseline</param_type>
            <param_value>0.938</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.056</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed informed consent throughout the treatment period and up to 14 days following the last dose of study drug.</time_frame>
      <desc>The Safety Population was defined as all subjects who were randomized to treatment regardless and received at least one dose of study treatment. Serious adverse events collected from the time the subject signed consent up to 14 days following the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>GP MDI</title>
          <description>Glycopyrronium Metered Dose Inhalation</description>
        </group>
        <group group_id="E2">
          <title>FF MDI</title>
          <description>FF MDI Formoterol Fumarate Metered Dose Inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Stenglein, MD</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+46 (0)31 776 1000</phone>
      <email>stephan.stenglein@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

